{
    "clinical_study": {
        "@rank": "14866", 
        "arm_group": [
            {
                "arm_group_label": "CSII", 
                "arm_group_type": "Active Comparator", 
                "description": "continuous subcutaneous insulin infusion for 2-4 weeks"
            }, 
            {
                "arm_group_label": "Liraglutide", 
                "arm_group_type": "Active Comparator", 
                "description": "continuous subcutaneous insulin infusion for 2-4 weeks combined with combined with Liraglutide 0.6mg/d for 2-4 weeks and 1.2mg/d for next 9 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate and evaluate the effects of liraglutide combined\n      with short-term continuous subcutaneous insulin infusion(CSII) on long-term glycemic control\n      and \u03b2-cell function in newly diagnosed type 2 diabetic patients."
        }, 
        "brief_title": "Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and \u03b2 Cell Function", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to investigate and evaluate the effects of liraglutide combined\n      with short-term continuous subcutaneous insulin infusion(CSII)(1.CSII alone; 2.liraglutide\n      combined with CSII) on long-term glycemic control and \u03b2-cell function in newly diagnosed\n      type 2 diabetic patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  newly diagnosed type 2 diabetes\n\n          -  fasting blood glucose (FBG) level ranging from 7.0-16.7mmol/L\n\n          -  body mass index (BMI) ranging from 21-35kg/m2\n\n          -  antihypercaemic and antihyperlipidemic medication-naive patients\n\n        Exclusion Criteria:\n\n          -  having any severe acute or chronic diabetic complications\n\n          -  renal dysfunction, blood creatinine>150umol/L\n\n          -  blood aminotransferase level rising up(more than 2 times of the upper normal limit of\n             ALT)\n\n          -  any severe cardiac disease including congestive cardiac failure, unstable angina or\n             myocardial infarct in 12 months\n\n          -  chronic or acute pancreatic disease\n\n          -  severe systemic diseases or malignant tumor\n\n          -  female patients incline to be pregnant\n\n          -  being treated with corticosteriod, immunosuppressing drugs or cytotoxic drugs\n\n          -  poor compliance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01790308", 
            "org_study_id": "13450149260"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "CSII", 
                    "Liraglutide"
                ], 
                "description": "continuous subcutaneous insulin infusion for 2~4 weeks", 
                "intervention_name": "CSII", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Liraglutide", 
                "description": "CSII for 2~4 weeks combined with Liraglutide 0.6mg/d for 1 month and 1.2mg/d for next 2 months", 
                "intervention_name": "Liraglutide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Glucagon-Like Peptide 1"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 11, 2013", 
        "number_of_arms": "2", 
        "official_title": "Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and \u03b2 Cell Function in Newly-diagnosed Type 2 Diabetic Patients", 
        "overall_official": {
            "affiliation": "Ministry of Education", 
            "last_name": "Yanbing Li, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "the percentage of the patients who maintain glucose control 1 year after short intensive therapy", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01790308"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Yanbing Li", 
            "investigator_title": "director of the endocrinology department of the First Affiliated Hospital of Sun Yat-sen University", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "the acute insulin response reflected \u03b2-cell function of different interventions in newly-diagnosed type 2 diabetic patients", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "the remission rate differ from interventions in newly-diagnosed type 2 diabetic patients", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}